Feasibility of peripheral blood stem cell collection from sickle cell trait donors with an intensified G‐CSF regimen

Abstract

ObjectivesAllogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for SCD and bone marrow from an HLA‐matched sibling is currently the standard of care. Haploidentical HSCT from a family donor with a TCR αβ/CD19 depleted graft (T‐haplo) is an increasingly successful alternative, which requires the generation of G‐CSF stimulated peripheral stem cell (PBSC) from haploidentical relatives. These sickle cell trait (SCT) donors reported to develop SCD‐related complications in conditions of severe stress.MethodsIn this retrospective analysis, we compared the safety and efficacy of PBSC mobilization with a G‐CSF intensified mobilization regimen in SCT donors with a conventional G‐CSF mobilization regimen in healthy donors.ResultsThe reported adverse events were similar during intensified G‐CSF mobilization, apheresis, and shortly after stem cell apheresis in SCT and control donors. In SCT and control donors, we were able to mobilize high yields of CD34+ stem cells and the harvested CD34+ cell count was comparable with control donors.ConclusionsPeripheral stem cell mobilization using an intensified G‐CSF regimen is safe, and well tolerated among SCT donors. SCT donors are a valid alternative for collection of peripheral CD34+ stem cells for T‐cell‐depleted haploidentical stem cell transplantation.